CA2483870A1 - Interacting site for gp41 on gp120 of hiv-1 - Google Patents

Interacting site for gp41 on gp120 of hiv-1 Download PDF

Info

Publication number
CA2483870A1
CA2483870A1 CA002483870A CA2483870A CA2483870A1 CA 2483870 A1 CA2483870 A1 CA 2483870A1 CA 002483870 A CA002483870 A CA 002483870A CA 2483870 A CA2483870 A CA 2483870A CA 2483870 A1 CA2483870 A1 CA 2483870A1
Authority
CA
Canada
Prior art keywords
amino acid
hiv
envelope protein
seq
chimera
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002483870A
Other languages
English (en)
French (fr)
Inventor
Gerald V. Quinnan, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2483870A1 publication Critical patent/CA2483870A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002483870A 2002-05-10 2003-05-12 Interacting site for gp41 on gp120 of hiv-1 Abandoned CA2483870A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37905202P 2002-05-10 2002-05-10
US60/379,052 2002-05-10
PCT/US2003/014721 WO2004045495A2 (en) 2002-05-10 2003-05-12 Interacting site for gp41 on gp120 of hiv-1

Publications (1)

Publication Number Publication Date
CA2483870A1 true CA2483870A1 (en) 2004-06-03

Family

ID=32326162

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002483870A Abandoned CA2483870A1 (en) 2002-05-10 2003-05-12 Interacting site for gp41 on gp120 of hiv-1

Country Status (6)

Country Link
US (1) US20080057492A1 (https=)
EP (1) EP1553978A4 (https=)
JP (1) JP2006504435A (https=)
AU (1) AU2003299489B2 (https=)
CA (1) CA2483870A1 (https=)
WO (1) WO2004045495A2 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
EP0651818B1 (en) * 1990-05-16 1999-01-07 Dana Farber Cancer Institute Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
ES2115622T5 (es) * 1990-10-17 2003-03-16 Us Health Clones moleculares de hiv-1 y usos de los mismos.
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
ATE435034T1 (de) * 1998-08-04 2009-07-15 Jackson H M Found Military Med Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.

Also Published As

Publication number Publication date
WO2004045495A3 (en) 2005-05-19
EP1553978A2 (en) 2005-07-20
JP2006504435A (ja) 2006-02-09
AU2003299489A1 (en) 2004-06-15
US20080057492A1 (en) 2008-03-06
AU2003299489B2 (en) 2009-01-15
EP1553978A4 (en) 2008-02-20
WO2004045495A2 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
US10946090B2 (en) Consensus/ancestral immunogens
Kayman et al. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains
US7666427B2 (en) HIV vaccines based on Env of multiple clades of HIV
AU700371B2 (en) Hiv envelope polypeptides
US20030165535A1 (en) Retrovirus-like particles made non-infectious by a plurality of mutations
IL127701A (en) HIV gp 120 ENVELOPE POLYPEPTIDES, VACCINE AND METHODS FOR THEIR PREPARATION
Srivastava et al. Role of neutralizing antibodies in protective immunity against HIV
Hammonds et al. Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core
Chakrabarti et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
US8048431B2 (en) Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
Montefiori et al. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
Cole et al. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain
Fox et al. Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site
AU762376C (en) Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
US20100080818A1 (en) Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response
MCKEATING et al. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera
JP5290576B2 (ja) 修飾されたｈｉｖ−１エンベロープタンパク質
AU2003299489B2 (en) Interacting site for gp41 on gp120 of HIV-1
US20030215793A1 (en) Complete genome sequence of a simian immunodeficiency virus from a wild chimpanzee
Protection Vaccination of Rhesus Macaques with

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued